Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET

Pediatric Surgery International

Volumn 24, Issue 5, 2008, Pages 521-530

  Moore, S W ^a   Zaahl, M G ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Children; Hirschsprung's disease; Multiple endocrine neoplasia syndromes; RET proto oncogene

Indexed keywords

PROTEIN RET;

CANCER RISK; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CODON; DISTANT METASTASIS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIRSCHSPRUNG DISEASE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTO ONCOGENE; RET ONCOGENE; REVIEW; SIPPLE SYNDROME; STEM CELL; THYROIDECTOMY; UPREGULATION;

CARCINOMA, MEDULLARY; CHILD; DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HIRSCHSPRUNG DISEASE; HUMANS; MITOGENS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; RISK FACTORS; THYROID NEOPLASMS;

EID: 42149115042     PISSN: 01790358     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00383-008-2137-5     Document Type: Review

References (109)

1. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30(2):216-222
2. Akhand AA, Ikeyama T, Akazawa S, Kato M, Hossain K, Takeda K, Suzuki H, Takahashi M, Nakashima I (2002) Evidence of both extra- and intracellular cysteine targets of protein modification for activation of RET kinase. Biochem Biophys Res Commun 292(4):826-831
3. Antinolo G, Marcos I, Fernandez RM, Romero M, Borrego S (2002) A novel germline point mutation, c.2304 G->T, in codon 768 of the RET proto-oncogene in a patient with medullary thyroid carcinoma. Am J Med Genet 110(1):85-87
4. Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, Carniti C, Perala NM, Pierotti MA, Sariola H (2004) Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol Endocrinol 18(4):1004-1017
5. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15(3):1613-1619
6. Auricchio A, Griseri P, Carpentieri ML, Betsos N, Staiano A, Tozzi A, Priolo M, Thompson H, Bocciardi R, Romeo G, Ballabio A, Ceccherini I (1999) Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease. Am J Hum Genet 64(4):1216-1221
7. Ball DW (2007) Medullary thyroid cancer: therapeutic targets and molecular markers.(Curr Opin Oncol 19(1):18-23
8. Barlow A, de Graaff E, Pachnis V (2003) Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET. Neuron 40(5):905-916
9. Blank E, Neerhout RC, Burry KA (1978) Congenital mesoblastic nephroma and polyhydramnios. JAMA 240:1504-1505
10. Blank RD, Sklar CA, Dimich AB, LaQuaglia MP, Brennan MF (1996) Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds. Cancer 78(9):1996-2003
11. Bolande RP (1974) The neurocristopathies, a unifying concept of disease arising in neural crest maldevelopment. Hum Pathol 5:409-429
12. Bolk S, Pelet A, Hofstra RM, Angrist M, Salomon R, Croaker D, Buys CH, Lyonnet S, Chakravarti A (2000) A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc Natl Acad Sci USA 97(1):268-273
13. Bonnet JP, Till M, Edery P, Attie T, Lyonnet S (1996) Waardenburg-Hirschsprung disease in two sisters: a possible clue to the genetics of this association. Eur J Pediatr Surg 6:245-248
14. Borrego S, Fernandez RM, Dziema H, Japon MA, Marcos I, Eng C, Antinolo G (2002) Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer. Thyroid 12(11):1017-1022
15. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G (1998) Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 83(9):3361-3364
16. Borrego S, Fernandez RM, Dziema H, Niess A, Lopez-Alonso M, Antinolo G, Eng C (2003) Investigation of germline GFRA4 mutations and evaluation of the involvement of GFRA1, GFRA2, GFRA3, and GFRA4 sequence variants in Hirschsprung disease. J Med Genet 40(3):e18
17. Borst MJ, VanCamp JM, Peacock ML, Decker RA (1995) Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 117(4):386-391
18. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658-5671
19. Brooks AS, Breuning MH, Osinga J, vd Smagt JJ, Catsman CE, Buys CH, Meijers C, Hofstra RM (1999) A consanguineous family with Hirschsprung disease, microcephaly, and mental retardation (Goldberg-Shprintzen syndrome). J Med Genet 36(6):485-489
20. Burzynski GM, Nolte IM, Osinga J, Ceccherini I, Twigt B, Maas S, Brooks A, Verheij J, Plaza Menacho I, Buys CH, Hofstra RM (2004) Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2. Eur J Hum Genet 12(8):604-612
21. Butter A, Gagne J, Al Jazaeri A, Emran MA, Deal C, St Vil D (2007) Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. J Pediatr Surg 42(1):203-206
22. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M (1996) Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J 15(11):2717-2725
23. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M (2006) The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57(3):391-395
24. Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, Goodfellow PJ (1994) Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55(6):1076-1082
25. Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S (1996) C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab 81(7):2731-2733
26. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M (1998) Dual effect on the RET receptor of MEN2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17(22):2851-2861
27. Costantini F, Shakya R. (2006) GDNF/Ret signaling and the development of the kidney. Bioessays 28(2):117-127
28. de Groot JW, Links TP, Rouwe CW, van der Wal JE, Hofstra RM, Plukker JT (2006) Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature. Ned Tijdschr Geneeskd 150(6):311-318
29. Decker RA, Peacock ML (1998) Occurrence of MEN2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg 33(2):207-214
30. Decker RA, Peacock ML, Watson P (1998) Hirschsprung disease in MEN2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 7(1):129-134
31. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr (1993) Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 2(7):851-856
32. Dralle H, Ukkat J, Brauckhoff M, Gimm O, Machens A (2004) Consortia experiences-can we cure MTC? J Intern Med 255(6):698-699
33. Drosten M, Putzer BM (2003) Gene therapeutic approaches for medullary thyroid carcinoma treatment. J Mol Med 81(7):411-419
34. Dvorakova S, Dvorakova K, Malikova M, Skaba R, Vlcek P, Bendlova B. (2005) A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease. J Pediatr Surg 40(6):e1-6
35. Edery P, Lyonnet S, Mulligan L et al (1994) Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367:378-380
36. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10(3):509-513
37. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3(2):237-241
38. Fernandez RM, Antinolo G, Eng C, Borrego S (2003) The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Hum Mutat 22(5):412-415
39. Fernandez RM, Antinolo G, Eng C, Borrego S (2003) The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Hum Mutat 22(5):412-415
40. Fitze G (2004) Management of patients with hereditary medullary thyroid carcinoma. Eur J Pediatr Surg 14(6):375-383
41. Fitze G, Saeger HD, Roesner D, Schackert HK (2004) Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene. Klin Padiatr 216(5):270-276
42. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155(2):229-236
43. Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M (1999) Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. Hum Mol Genet 8(11):1989-1999
44. Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79(3):564-573
45. Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H (2004) Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28(12):1312-1316
46. Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, Ceccherini I (2005) A common haplotype at the 5′ end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression. Hum Mutat 25(2):189-195
47. Gujral TS, Mulligan LM (2006) Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. Ann NY Acad Sci 1073:234-240
48. Guyetant S, Blechet C, Saint-Andre JP (2006) C-cell hyperplasia. Ann.Endocrinol (Paris) 67(3):190-197
49. Hazard JB, Hawk WA, Crile G Jnr (1959) Medullary (solid) carcinoma of the thyroid:a clinicopathologic entity. J Clin Endocrinol Metab 19:152-161
50. Inoue K, Shimotake T, Inoue K, Tokiwa K (1999) Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Pediatr Surg 34(10):1552-1554
51. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M (1997) Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 57(14):2870-2872
52. Iwashita T, Murakami H, Asai N, Takahashi M (1996) Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet 5(10):1577-1580
53. Kebebew E, Clark OH (2000) Medullary thyroid cancer. Curr Treat Options.Oncol 1(4):359-367
54. Khan AH, Desjardin JG, Gregoire H, Seidman E (1987) Gastrointestinal manifestations of the Sipple syndrome in children. J Pediatr Surg 22:719-723
55. Kjaer S, Ibanez CF (2003) Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET. J Biol Chem 278(48):47898-47904
56. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF, McDonald NQ (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281(44):33577-33587
57. Lantieri F, Griseri P, Puppo F, Campus R, Martucciello G, Ravazzolo R, Devoto M, Ceccherini I. (2006) Haplotypes of the human RET proto-oncogene associated with Hirschsprung disease in the Italian population derived from a single ancestral combination of alleles. Ann Hum Genet 70(Pt 1):12-26
58. Luo Y, Barone V, Seri M, Bolino A, Bocciardi R, Ceccherini I, Pasini B, Tocco T, Lerone M, Cywes S, Moore S, Vanderwinden JM, Abramowicz MJ, Kristofferson U, Hamel B, Martucciello G, Romeo G (1994) Heterogeneity of mutations of the RET proto-oncogene in autosomal dominant HSCR. Eur J Hum Genet 2:272-280
59. Luo Y, Ceccherini I, Pasini B, et al (1993) Close linkage with the RET proto-oncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet. 2:1803-1808
60. Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90(4):2029-2034
61. Machens A, Dralle H (2006) DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer. Surgery 139(3):279-282
62. Machens A, Dralle H (2006) Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol 247(1-2):34-40
63. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H (2001) Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86(3):1104-1109
64. Machens A, Holzhausen HJ, Thanh PN, Dralle H (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134(3):425-431
65. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H (2005) Advances in the management of hereditary medullary thyroid cancer. J Inter Med 257(1):50-59
66. Martuciello G, Bicocci MP, Dodero P, Lerone M, Silengo-Cirillo M, Puliti A, Gimelli G (1992) Total colonic aganglionosis associated with intestitial deletion of the long arm of chromosome 10. Pediatr Surg Int 7(4):308-310
67. Moore SW, Appfelstaedt J, Zaahl MG (2007) Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg 42(2):326-332
68. Moore SW, Appfelstaedt J, Zaahl MG (2007) Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J.Pediatr.Surg 42(2):326-332
69. Mulligan LM, Eng C, Healey CS, Ponder MA, Feldman GL, Li P, Jackson CE, Ponder BA. (1994) A de novo mutation of the RET proto-oncogene in a patient with MEN2A. Hum Mol Genet 3(6):1007-1008
70. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428):458-460
71. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M et al (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238(4):343-346
72. Musholt PB, Musholt TJ, Goodfellow PJ, Zehnbauer BA, Wells SA, Moley JF (1997) "Cold" single-strand conformational variants for mutation analysis of the RET proto-oncogene. Surgery 122(2):363-370
73. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57(9):1690-1694
74. Nishikawa M, Murakumo Y, Imai T, Kawai K, Nagaya M, Funahashi H, Takahashi M (2003) Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease. Eur J Hum Genet 11(5):364-368
75. Pakarinen MP, Rintala RJ, Koivusalo A, Heikkinen M, Lindahl H, Pukkala E (2005) Increased incidence of medullary thyroid carcinoma in patients treated for Hirschsprung's disease. J Pediatr Surg 40(10):1532-1534
76. Pasini B, Rossi R, Ambrosio MR, Zatelli MC, Gullo M, Gobbo M, Collini P, Pansini G, Trasforini G, degli Uberti EC (2002) RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 131(4):373-381
77. Passarge E (1967) The genetics of Hirschsprung's disease. N Engl J Med 276:138-143
78. Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, Pelicci PG (2002) The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 22(20):7351-7363
79. Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, Grynberg E, Yakobson E, Lapidot M (1997) Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat 10(2):155-159
80. Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F (2006) Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 72(4):405-414
81. Pingault V, Bondurand N, Kuhlbrodt K, Goerich DE, Prehu MO, Puliti A, Herbarth B, Hermans-Borgmeyer I, Legius E, Matthijs G, Amiel J, Lyonnet S, Ceccherini I, Romeo G, Smith JC, Read AP, Wegner M, Goossens M (1998) SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 18(2):171-173
82. Pinna G, Orgiana G, Riola A, Ghiani M, Lai ML, Carcassi C, Mariotti S (2007) RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 17(2):101-104
83. Rakover Y, Dharan M, Luboshitsky R (1994) Hirschsprung's disease associated with isolated familial medullary carcinoma of the thyroid. J Pediatr Endocrinol 7(4):373-377
84. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G (1998) Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 243(6):515-520
85. Romeo G, McKusick V (1994) Phenotypic diversity, alleic series and modifier genes. Nat.Genet 7:451-453
86. Russo A, Zanna I, Tubiolo C, Migliavacca M, Bazan V, Latteri MA, Tomasino RM, Gebbia N (2000) Hereditary common cancers: molecular and clinical genetics. Anticancer Res 20(6C):4841-4851
87. Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M (2001) Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 61(4):1426-1431
88. Sancandi M, Griseri P, Pesce B, Patrone G, Puppo F, Lerone M, Martucciello G, Romeo G, Ravazzolo R, Devoto M, Ceccherini I (2003) Single nucleotide polymorphic alleles in the 5′ region of the RET proto-oncogene define a risk haplotype in Hirschsprung's disease. J Med Genet 40(9):714-718
89. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G (1995) Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 133(5):513-522
90. Sariola H, Saarma M (2003) Novel functions and signalling pathways for GDNF. J Cell Sci 116(Pt 19):3855-3862
91. Sasaki Y, Shimotake T, Go S, Iwai N (2001) Total thyroidectomy for hereditary medullary thyroid carcinoma 12 years after correction of Hirschsprung's disease. Eur J Surg 167(6):467-469
92. Schocket E, Telok HA (1957) Aganglionic megacolon, phaeochromocytoma, megaloureter and neurofibromatosis. Am J Dis Child 94:185-191
93. Schuchardt A, D'Agati V, Larsson-Blomberg L, Constanini F, Pachnis V (1994) Defects in the kidney and enteric system of mice lacking the tyrosine- kinase receptor ret. Nature 367:380-383
94. Shocket E, Teloh HA (1957) Aganglionic megacolon, phaeochromocytoma, megaloureter and neurofibromatosis. Am J Dis Child 94:185-191
95. Sijmons RH, Hofstra RM, Wijburg FA, Links TP, Zwierstra RP, Vermey A, Aronson DC, Tan-Sindhunata G, Brouwers-Smalbraak GJ, Maas SM, Buys CH. (1998) Oncological implications of RET gene mutations in Hirschsprung's disease. Gut 43(4):542-547
96. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Jackson CE, Duncan AM, Farrer LA, Brasch K (1987) Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328(6130):528-530
97. Sipple JH (1961) The association of phaeochromocytomas with carcinomas of the thyroid gland. Am J Med 31:163-166
98. Skaba R, Dvorakova S, Vaclavikova E, Vlcek P, Frantlova M, Bendlova B (2006) The risk of medullary thyroid carcinoma in patients with Hirschsprung's disease. Pediatr Surg Int 22(12):991-995
99. Skinner MA (2003) Management of hereditary thyroid cancer in children. Surg Oncol 12(2):101-104
100. Steiner AL, Goodman AD, Powers SR (1968) Study of a kindred with phaeochromocytoma, medullary thyroid carcinoma, hyperparathyroidism, and Cushings disease:multiple endocrine neoplasia. Medicine (Baltimore) 47:371-409
101. Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42(2):581-588
102. Takahishi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M (1999) Co-segregation of MEN2 and Hirschsprung's disease: the same mutation with both gain and loss of function. Hum Mutat 13(4):331-336
103. Toledo SPA, Cortina MA, Toledo RA et al (2006) Impact of RET protooncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics 61:59-70
104. Torre M, Martucciello G, Ceccherini I, Lerone M, Aicardi M, Gambini C, Jasonni V. (2002) Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B in pediatric patients. Pediatr Surg Int 18(5-6):378-383
105. van Heyningen V (1994) Genetics. One gene-four syndromes. Nature 367(6461):319-320
106. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. (1982) Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1(4):603-607
107. Williams ED, Pollock DJ (1966) Multiple mucosal neuromata with endocrine tumours:a syndrome allied to von Recklinghausens disease. J Pathol Bacteriol 91:71-80
108. Wong A, Bogni S, Kotka P, de Graaff E, D'Agati V, Costantini F, Pachnis V (2005) Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol Cell Biol 25(21):9661-9673
109. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB (2003) Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138(4):409-416